JP2025509568A5 - - Google Patents
Info
- Publication number
- JP2025509568A5 JP2025509568A5 JP2024554787A JP2024554787A JP2025509568A5 JP 2025509568 A5 JP2025509568 A5 JP 2025509568A5 JP 2024554787 A JP2024554787 A JP 2024554787A JP 2024554787 A JP2024554787 A JP 2024554787A JP 2025509568 A5 JP2025509568 A5 JP 2025509568A5
- Authority
- JP
- Japan
- Prior art keywords
- weeks
- regimen
- dose
- patient
- vegf antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263320796P | 2022-03-17 | 2022-03-17 | |
| US63/320,796 | 2022-03-17 | ||
| US202263386380P | 2022-12-07 | 2022-12-07 | |
| US63/386,380 | 2022-12-07 | ||
| PCT/IB2023/052565 WO2023175549A1 (en) | 2022-03-17 | 2023-03-16 | Methods for treating neovascular age-related macular degeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509568A JP2025509568A (ja) | 2025-04-11 |
| JP2025509568A5 true JP2025509568A5 (https=) | 2026-03-25 |
Family
ID=85873755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024554787A Pending JP2025509568A (ja) | 2022-03-17 | 2023-03-16 | 新生血管加齢性黄斑変性を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250197486A1 (https=) |
| EP (1) | EP4493589A1 (https=) |
| JP (1) | JP2025509568A (https=) |
| TW (1) | TW202337496A (https=) |
| WO (1) | WO2023175549A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1802334E (pt) | 2004-10-21 | 2012-11-28 | Genentech Inc | Método para tratamento de doenças neovasculares intraoculares |
| BRPI0914251B1 (pt) | 2008-06-25 | 2022-07-19 | Novartis Ag | Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição |
| TW202116802A (zh) * | 2019-09-13 | 2021-05-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
-
2023
- 2023-03-15 TW TW112109645A patent/TW202337496A/zh unknown
- 2023-03-16 WO PCT/IB2023/052565 patent/WO2023175549A1/en not_active Ceased
- 2023-03-16 EP EP23715230.1A patent/EP4493589A1/en active Pending
- 2023-03-16 US US18/846,943 patent/US20250197486A1/en active Pending
- 2023-03-16 JP JP2024554787A patent/JP2025509568A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2025271125A1 (en) | Methods for treating or preventing ophthalmological conditions | |
| JP6746495B2 (ja) | ベンラリツマブを使用して喘息の増悪率を低減する方法 | |
| TW202323296A (zh) | 組合療法 | |
| JP2025509568A5 (https=) | ||
| JP7050335B2 (ja) | 骨形成不全症の処置における抗スクレロスチン抗体の使用 | |
| EP4670788A2 (en) | TREATMENT METHODS FOR PSORIASIS USING IL-17 ANTAGONISTS | |
| JP2022547541A5 (https=) | ||
| JP2016516016A5 (https=) | ||
| JP2020100653A (ja) | ベンラリツマブによる喘息症状の改善方法 | |
| Kim et al. | Clinical trials in noninfectious uveitis | |
| JP2022062153A (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| JP2025506383A5 (https=) | ||
| US20210130464A1 (en) | Methods and Compositions for Reducing Immunogenicity By Non-Depletional B Cell Inhibitors | |
| JP2019519584A5 (https=) | ||
| US20220127346A1 (en) | Methods of Safe Administration of Anti-Tau Antibody | |
| JP2025506681A5 (https=) | ||
| Graul et al. | The year's new drugs and biologics 2019 | |
| WO2017221174A1 (en) | Methods of treating vitiligo using interleukin-17 (il-17) antibodies | |
| AU2021293980B2 (en) | Treatment of food allergy using anti-IgE antibodies | |
| RU2848183C1 (ru) | Лечение болезни паркинсона | |
| US20230235041A1 (en) | Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists | |
| Schreiber et al. | T1133 efficacy and tolerability of certolizumab pegol are sustained over 18 months: Data from PRECISE 2 and its extension studies (PRECISE 3 and 4) | |
| IL317086A (en) | Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists | |
| AU2020396455A1 (en) | Methods of treating lichen planus using Interleukin-17 (IL-17) antagonists | |
| Fasanmade et al. | T1132 Pharmacokinetics and Exposure-Response Relationship of Ustekinumab, a Human Monoclonal Antibody to Interleukin 12/23, in Patients with Moderate-to-Severe Crohn's Disease |